A recent spate of worrying clinical-trial data has researchers questioning drugs approved on the basis of how they affect biomarkers rather than clinical endpoints. Heidi Ledford looks at surrogate markers.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Nissen, S. E. & Wolski, K. N. Engl. J. Med. 356, 2457-2471 (2007).
Kastelein, J. J. P. N. Engl. J. Med. 358, 1431-1443 (2008).
Prentice, R. L. et al. Am. J. Epidemiol. 163, 589-599 (2006).
Cardiac Arrhythmia Suppression Trial Investigators N. Engl. J. Med. 321, 406-412 (1989).
Cardiac Arrhythmia Suppression Trial II Investigators N. Engl. J. Med. 327, 227-233 (1992).
Temple, R. J. in Clinical Measurement in Drug Evaluation (eds Nimmo, W. S. & Tucker, G. T.) (Wiley, New York, 1995).
Related links in Nature Research
Nature Insight: Obesity and Diabetes
Nature Insight: Cardiovascular Disease
Related external links
Rights and permissions
About this article
Cite this article
Ledford, H. Drug markers questioned. Nature (2008). https://doi.org/10.1038/452510a
This article is cited by
Off-tumor target—beneficial site for antiangiogenic cancer therapy?
Nature Reviews Clinical Oncology (2010)